NSCLC metastatic/no molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 24/06/2020)

1st line
LUNG037 (Merck)
A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer.

2th line 
Carmen (Sanofi)
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients.

3th line
Currently no trials